# US 2010/0143911 A1 · Method for screening essential metabolites in growth of microorganisms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143911 A1
- Document ID: US20100143911A1
- Status: Published application
- Kind: A1
- Application number: 12/519,791
- Filed: 2007-12-21
- Published: 2010-06-10
- Earliest claimed: 2006-12-22
- Assignees: Korea Advanced Institute of Science and Technology
- Inventors: Sang Yup Lee; Hawoong Jeong; Tae Yong Kim; Pan-Jun Kim; Kwang Ho Lee
- Web page: https://patentgrep.com/patent/US20100143911A1

## CPC

- C12Q 1/18: Testing for antimicrobial activity of a material
- G01N 33/5038: {involving detection of metabolites per se}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention disclosed is a method for screening metabolites essential for the growth of microorganism using metabolic flux analysis. More specifically, the present invention relates to the method for screening metabolites essential for the growth of microorganism, by selecting a target microorganism, constructing a metabolic network model of the selected microorganism, inactivating the consumption reaction of each of metabolites in the constructed metabolic network model, analyzing the metabolic flux of the metabolites to select metabolites essential for the growth of the microorganism, and confirming the selected metabolites using the utilization of each of the metabolites, defined as flux sum (Φ). According to the present invention, metabolites essential for the growth of microorganism, and genes involved in the essential metabolites, can be screened in a convenient manner, and drug-target genes against pathogenic microorganisms can be predicted by deleting genes associated with the metabolites screened according to the method.

## Claims

### Claim 1

A method for screening metabolites essential for the growth of a microorganism using metabolic flux analysis, the method comprising the steps of:
(a) selecting a target microorganism and constructing a metabolic network model of the selected microorganism; and
(b) inactivating the consumption reaction of each of metabolites in the constructed metabolic network model, analyzing the metabolic flux of each of the metabolites, and selecting, metabolites showing a less than 50% decrease in cell growth rate, compared to the normal growth rate as metabolites essential for the growth of the microorganism, using Equation 2 below:
f
=
r
loss
r
wild
[
Equation


2
]
wherein rwild represents the normal cell growth rate, and rloss represents cell growth rate which decreases when the consumption reaction of the relevant metabolite is inactivated.

### Claim 2 (depends on 1)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to claim 1, wherein the inactivation of the consumption reaction of each of the metabolites is performed by setting the value of metabolic flux of the consumption reaction to zero (0).

### Claim 3 (depends on 1)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to claim 1, which further comprises the steps of:
(c) defining the utilization of the metabolites selected in the step (b), as flux sum (Φ) represented by Equation 3 below, and then calculating the flux sum (Φ) of each of the metabolites:
Φ
i
=
∑
j
∈
P
i


S
ij

v
j
=
-
∑
j
∈
C
i


S
ij

v
j
=
1
2

∑
j



S
ij

v
j

[
Equation


3
]
wherein Φi is the flux sum (Φ) of the ith metabolite, Sij is the stoichiometric coefficient of the ith metabolite in the jth reaction, vj is the metabolic flux of the jth reaction, Pi is a set of metabolic reactions producing the ith metabolite, and Ci is a of metabolic reactions consuming the ith metabolite; and
(d) determining metabolites showing a decrease or stop in the growth of cells when the flux sum (Φ) of each metabolite is reduced, as metabolites essential for the growth of the microorganism.

### Claim 4 (depends on 1, 2, 3)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to any one claim among claims 1-3, wherein the essential metabolites are selected from the group consisting of: H+, H2O, ATP, phosphate, ADP, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide-reduced, CO2, nicotinamide adenine dinucleotide phosphate, pyruvate, nicotinamide adenine dinucleotide phosphate-reduced, L-glutamate, coenzyme A, ammonium, AMP, acetyl-CoA, 2-oxoglutarate, acyl carrier protein, phosphoenolpyruvate, L-aspartate, L-glutamine, glyceraldehyde 3-phosphate, CMP, glycerol 3-phosphate, GTP, 5-phospho-alpha-D-ribose 1-diphosphate, dihydroxyacetone phosphate, L-alanine, L-serine, D-fructose 6-phosphate, malonyl-[acyl-carrier protein], D-gucose 1-phosphate, GDP, oxaloacetate, reduced thioredoxin, FAD, D-glucose 6-phosphate, oxidized thioredoxin, UMP, CTP, S-adenosyl-L-methionine, L-cysteine, alpha-D-ribose 5-phosphate, UDP-glucose, 5,6,7,8-tetrahydrofolate, acetoacetyl-ACP, UDP, UTP, succinyl-CoA, L-threonine, putrescine, glycine, GMP, spermidine, IMP, phosphatidylglycerol, L-arginine, L-lysine, 5,10-methylenetetrahydrofolate, chorismate, D-alanine, L-proline, L-asparagine, UDP-N-acetyl-D-glucosamine, D-glucosamine 6-phosphate, nicotinate D-ribonucleotide, dGTP, iminoaspartate, D-ribulose 5-phosphate, myristoyl-ACP (n-C14:0ACP), 3-methyl-2-oxobutanoate, L-methionine, L-tryptophan, dTMP, phosphatidate, L-valine, bicarbonate, dCTP, dUMP, L-glutamate 5-semialdehyde, meso-2,6-diaminoheptanedioate, CMP-3-deoxy-D-manno-octulosonate, undecaprenyl diphosphate, L-isoleucine, phosphatidylethanolamine, L-leucine, L-histidine, hexadecenoyl-ACP(n-C16:1ACP), 1-pyrroline-5-carboxylate, sulfite, carbamoyl phosphate, D-erythrose 4-phosphate, 3-phospho-D-glycerate, CDP-diacylglycerol, xanthosine 5′-phosphate, dTTP, L-tyrosine, L-homocysteine, dATP, 10-formyltetrahydrofolate, R-3-hydroxy-myristoyl-ACP, octadecenoyl-ACP (n-C18:1ACP), palmitoyl-ACP (n-C16:0ACP), (S)-dihydroorotate, tetradecenoyl-ACP (n-C14:1ACP), 2-oxobutanoate, 5-amino-1-(5-Phospho-D-ribosyl)imidazole-4-carboxamide, L-phenylalanine, phosphatidylserine, UDP-2,3-bis(3-hydroxytetradecanoyl)glucosamine, L-homoserine, undecaprenyl phosphate, (R)-pantothenate, orotate, L-aspartate 4-semialdehyde, sedoheptulose 7-phosphate, N2-formyl-N-1-(5-phospho-D-ribosyl)glycinamide, 5-methyltetrahydrofolate, hydrogen sulfide, 7,8-dihydrofolate, dTDP, glycogen, dodecanoyl-ACP(n-C12:0ACP), 4-(1-D-ribitylamino)-5-aminouracil, prephenate, 5-amino-1-(5-phospho-D-ribosyl)imidazole, KDO(2)-lipid IV(A), N1-(5-phospho-D-ribosyl)glycinamide, 5-[(5-phospho-1-deoxyribulos-1-ylamino)methylideneamino]-1-(5-phosphoribosyl)imidazole-4-carboxamide, phosphatidylglycerophosphate, UDP-N-acetylmuramoyl-L-alanine, N-succinyl-LL-2,6-diaminoheptanedioate, 2-dehydro-3-deoxy-D-arabino-heptonate 7-phosphate, O-phospho-L-serine, UDP-N-acetylmuramate, (S)-2-[5-amino-1-(5-phospho-D-ribosypimidazole-4-carboxamido]succinate, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, 3-carboxy-3-hydroxy-4-methylpentanoate, 2,3-bis(3-hydroxytetradecanoyl)-beta-D-glucosaminyl 1-phosphate, 3-deoxy-D-manno-octulosonate 8-phosphate, N—((R)-4-phosphopantothenoyl)-L-cysteine, peptidoglycan subunit of E. coli, adenosine 5′-phosphosulfate, dihydropteroate, 3-dehydroshikimate, 1-(5-phosphoribosyl)-AMP, 4-methyl-2-oxopentanoate, D-glycero-D-manno-heptose 7-phosphate, 2,3,4,5-tetrahydrodipicolinate, 3-phosphohydroxypyruvate, D-glycero-D-manno-heptose 1-phosphate, D-erythro-1-(imidazol-4-yl)glycerol 3-phosphate, sulfate, UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine, 2-amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, UDP-3-O-(3-hydroxytetradecanoyl)-D-glucosamine, orotidine 5′-phosphate, UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine, 6-hydroxymethyl dihydropterin, O-acetyl-L-serine, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, cardiolipin, (R)-2,3-dihydroxy-3-methylbutanoate, (S)-2-acetolactate, 3′-phosphoadenylyl sulfate, 1-(5-phosphoribosyl)-ATP, 2,3,2′3′-tetrakis(beta-hydroxymyristoyl)-D-glucosaminyl-1,6-beta-D-glucosamine 1,4′-bisphosphate, shikimate 5-phosphate, (R)-pantoate, 2-dehydropantoate, CDP-ethanolamine, 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate, 5-phospho-beta-D-ribosylamine, N-succinyl-2-L-amino-6-oxoheptanedioate, D-4′-phosphopantothenate, 3-deoxy-D-manno-2-octulosonate, ADP-L-glycero-D-manno-heptose, beta-alanine, D-alanyl-D-alanine, O-succinyl-L-homoserine, quinolinate, 2-(formamido)-N1-(5-phospho-D-ribosyl)acetamidine, D-arabinose 5-phosphate, 145-phosphoribosyl)-5-[(5-phosphoribosylamino) methylideneamino]imidazole-4-carboxamide, lipopolysaccharide, 6-hydroxymethyl-dihydropterin pyrophosphate, shikimate, undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-ala-D-glu-meso-2,6-diaminopimeloyl-D-ala-D-ala, 5-phosphoribosyl-5-carboxyaminoimidazole, 3-carboxy-2-hydroxy-4-methylpentanoate, N-acetyl-D-glucosamine 1-phosphate, L-cystathionine, (S)-3-methyl-2-oxopentanoate, 5-O-(1-carboxyvinyl)-3-phosphoshikimate, 2-amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate, D-glycero-D-manno-heptose 1,7-bisphosphate, 3-(imidazol-4-yl)-2-oxopropyl phosphate, 3,4-dihydroxy-2-butanone 4-phosphate, KDO(2)-lipid IV(A) with laurate, 2-isopropylmaleate, KDO-lipid IV(A), ADP-D-glycero-D-manno-heptose, KDO(2)-lipid (A), N6-(1,2-dicarboxyethyl)-AMP, 5-formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide, lipid A disaccharide, 2,3-dihydrodipicolinate, 3-dehydroquinate, 4-phospho-L-aspartate, S-adenosylmethioninamine, 3-carboxy-4-methyl-2-oxopentanoate, phenylpyruvate, D-glucosamine 1-phosphate, dephospho-CoA, ADP-glucose, 4-aminobenzoate, L-histidinol phosphate, LL-2,6-diaminoheptanedioate, dihydroneopterin monophosphate, pantetheine 4′-phosphate, N-carbamoyl-L-aspartate, (R)-2,3-dihydroxy-3-methylpentanoate, malonyl-C oA, 4-amino-4-deoxychorismate, D-glutamate, 3-(4-hydroxyphenyl)pyruvate, L-histidinol, deamino-NAD+, and (S)-2-aceto-2-hydroxybutanoate.

### Claim 5 (depends on 3)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to claim 3, wherein the type of the decrease in the cell growth according to the decrease in flux sum (Φ) is selected from the group consisting of: a type in which the cell growth linearly decreases; a type in which the cell growth decreases below a critical value, and a type in which the cell growth decreases non-linearly, such that the cell growth stops before the flux sum (Φ) reaches zero (0).

### Claim 6 (depends on 5)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to claim 5, wherein the perturbation of the flux sum (Φ) varies depending on the type of the decrease in the cell growth.

### Claim 7 (depends on 1)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to claim 1, wherein the target microorganism is E. coli.

### Claim 8 (depends on 1, 2, 3)

The method for screening metabolites essential for the growth of microorganism using metabolic flux analysis according to any one claim among claims 1-3, wherein the target microorganism is a pathogenic microorganism.

### Claim 9 (depends on 1, 2, 3)

A method for screening genes essential for the growth of microorganism, the method comprise screening genes involved in the metabolites essential for the growth of microorganism screened by the method of any one claim among claims 1-3.

### Claim 10 (depends on 9)

The method for screening genes essential for the growth of microorganism according to claim 9, wherein the microorganism is E. coli.

### Claim 11 (depends on 9)

The method for screening genes essential for the growth of microorganism according claim 9, wherein the microorganism is a pathogenic microorganism.

### Claim 12 (depends on 10)

A method for producing a transformed microorganism, the method comprises transforming a model microorganism with the genes essential for the growth of E. coli screened by the method of claim 10.

### Claim 13 (depends on 11)

A method for producing a transformed microorganism, the method comprises transforming a model microorganism with the genes essential for the growth of the pathogenic microorganism screened by the method of claim 11.

### Claim 14 (depends on 12)

A transformed microorganism produced by the method of claim 12 and transformed with genes essential for the growth of E. coli.

### Claim 15 (depends on 13)

A transformed microorganism produced by the method of claim 13 and transformed with genes essential for the growth of a pathogenic microorganism.

### Claim 16 (depends on 15)

A method for screening substances inhibiting the growth of a pathogenic microorganism, the method comprising the steps of
(a) culturing said transformed microorganism of claim 15 in the presence of an inhibitor candidate of the growth of the pathogenic microorganism; and
(b) selecting a candidate showing the inhibition of the growth of the transformed microorganism compared to the case where the transformed microorganism is cultured in the absence of the growth inhibitor candidate, as a substance inhibiting the growth of pathogenic microorganism.
